Non-communicable diseases, such as cardiovascular diseases, are the leading cause of mortality worldwide. For this reason, a tremendous effort is being made worldwide to effectively circumvent these afflictions, where insulin-like growth factor 1 (IGF1) is being proposed both as a marker and as a central cornerstone in these diseases, making it an interesting molecule to focus on. Firstly, at the initiation of metabolic deregulation by overfeeding, IGF1 is decreased/inhibited. Secondly, such deficiency seems to be intimately related to the onset of MetS and establishment of vascular derangements leading to atherosclerosis and finally playing a definitive part in cerebrovascular and myocardial accidents, where IGF1 deficiency seems to render these organs vulnerable to oxidative and apoptotic/necrotic damage. Several human cohort correlations together with basic/translational experimental data seem to confirm deep IGF1 implication, albeit with controversy, which might, in part, be given by experimental design leading to blurred result interpretation.
CITATION STYLE
Aguirre, G. A., González-Guerra, J. L., Espinosa, L., & Castilla-Cortazar, I. (2018). Insulin-like growth factor 1 in the cardiovascular system. In Reviews of Physiology, Biochemistry and Pharmacology (Vol. 175, pp. 1–45). Springer Verlag. https://doi.org/10.1007/112_2017_8
Mendeley helps you to discover research relevant for your work.